Quantcast

Latest APG101 Stories

2014-08-31 23:02:00

Doctors at Atlantic NeuroSurgical Specialists (ANS) have added a new and innovative form of therapy to their treatment arsenal in the battle against glioblastoma multiforme (GBM). Affecting nearly 10,000 Americans annually, GBM is the one of the most aggressive and difficult-to-control forms of primary brain tumors in the United States. Morristown, NJ (PRWEB) August 31, 2014 Describing the NovoTTFTM system as a “cell division taser device,” Dr. Yaron Moshel explains that the NovoTTF...

2014-08-27 23:02:42

NovoTTF™-100A System Offers Novel, Non-Invasive Treatment in Fight Against an Aggressive Type of Brain Cancer Morristown,NJ (PRWEB) August 27, 2014 ANS is pleased to announce the availability of NovoTTF-100A System, a ground breaking anti-cancer therapy for the treatment of recurrent glioblastoma (GBM). Experts at ANS are now certified to prescribe this new medical therapy and will begin extending this new treatment option for recurrent GBM patients starting immediately. NovoTTF™...

2014-08-07 23:09:09

NuvOx Pharma, a Tucson based biotechnology company, began a Phase Ib clinical trial of its new drug NVX-108 in patients with glioblastoma, a deadly form of brain cancer. Tucson, AZ (PRWEB) August 07, 2014 NuvOx Pharma, a privately held biotechnology company based in Tucson, Arizona, focused on developing a nanotechnology platform for reversing conditions with decreased oxygen announced that on July 14th, it began a Phase Ib clinical trial of its new drug NVX-108 in patients with...

2014-08-04 08:27:33

- Results from Phase I program in glioblastoma multiforme presented at ASCO earlier this year NORTH CHICAGO, Ill., Aug. 4, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with...

2014-05-31 08:20:41

VANCOUVER, British Columbia and MENLO PARK, Calif., May 31, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago. In...

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-16 08:26:16

30mg/m2 dose cohort had been completed; enrollment of 40mg/m2 cohort has been initiated VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to provide an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma multiforme (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 6 and advanced to Cohort 7. DelMar most recently presented...

2014-04-09 12:31:10

VAL-083 therapy is well tolerated to date; dose limiting toxicity has not been reached after fifth cohort (20mg/m2) VANCOUVER, British Columbia and MENLO PARK, Calif., April 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in...

2014-01-13 08:30:13

Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan. 13, 2014 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today the successful completion of its phase II proof-of-concept trial with APG101 in patients with recurrent glioblastoma. All endpoints of the randomized controlled trial that compared the efficacy and safety of a combination therapy of APG101 and radiotherapy versus radiotherapy alone were achieved or...

2014-01-07 08:32:13

HEIDELBERG, Germany, Jan. 7, 2014 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today that Thomas Hoeger, Ph.D., Chief Executive Officer, will present the results of the completed phase II efficacy trial in patients with recurrent glioblastoma at the Biotech Showcase(TM) in San Francisco. The presentation will take place on Tuesday, Jan. 14, at 4 p.m. PST at the Parc 55 Wyndham San Francisco - Union Square. "The results of this controlled phase II...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.